Medartis Holding AgSIX: MED

Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year

Aug 19, 2025 at 5:02 AM UTC · Issued by Medartis Holding AG

Medartis Holding AG / Key word(s): Half Year Results
Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year

19-Aug-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement.

Total sales reached CHF 123.0 million, including NeoOrtho business in Brazil from May onwards
Core sales rose organically^[1] by 15.3% (CER), driven by mid-teens growth in EMEA and US
Core^[2] EBITDA margin sustained at 17.8% despite pressure from CHF appreciation and US tariffs
Company secured the remaining 53% stake in KeriMedical in July and is preparing for US market entry of its flagship product TOUCH
NeoOrtho integration in Brazil on plan; back-office consolidation and new production facility in Curitiba to be concluded early 2026
Guidance 2025: Medartis expects organic growth in core sales of 14-16%, along with an unchanged high-teens core EBITDA margin despite additional headwind from the US tariffs

<div><p><strong>dHALF-YEAR 2025 KEY FINANCIALS</strong><br/><strong> </strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: bottom;"><p><span><span>in CHF million,</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p><span><span>H1 2025</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p><span><span>H1 2024</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td colspan="2" style="vertical-align: middle;"><p><span><span>Organic growth<sup>1</sup><br/> of core business</span></span></p></td></tr><tr><td style="vertical-align: top;"><p><span><span>rounded</span></span></p></td><td style="vertical-align: top;"><p><span><span>Reported</span></span></p></td><td style="vertical-align: top;"><p><span><span>Non-core items<sup>2</sup></span></span></p></td><td style="vertical-align: top;"><p><span><span>Core</span></span></p></td><td style="vertical-align: top;"><p><span><span>Reported</span></span></p></td><td style="vertical-align: top;"><p><span><span>Non-core items<sup>2</sup></span></span></p></td><td style="vertical-align: top;"><p><span><span>Core</span></span></p></td><td style="vertical-align: top;"><p><span><span>in CHF</span></span></p></td><td style="vertical-align: top;"><p><span><span>at CER</span></span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>Net sales</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>123.0</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(1.0)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>122.1</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>111.5</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(3.9)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>107.6</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>11.4%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>15.3%</span></span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>Gross profit</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>97.8</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>0.7</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>98.5</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>89.6</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>0.2</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>89.7</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>EBITDA</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>21.0</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>0.8</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>21.7</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>23.9</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(4.7)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>19.1</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>EBIT</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>9.3</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>1.1</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>10.4</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>3.5</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>5.7</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>9.2</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>Net profit / loss</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>-1.3</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>0.9</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>-0.4</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>2.6</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>4.7</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>7.3</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td></tr><tr><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p> </p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>Margins in % of sales</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td colspan="2" style="vertical-align: middle;"><p><span><span>Change in %-points (PP)<br/> of core business</span></span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>Gross profit</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>79.5%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>80.7%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>80.3%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>83.4%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(2.7 PP)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(2.1 PP)</span></span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>EBITDA</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>17.0%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>17.8%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>21.4%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>17.8%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(0.0 PP)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>1.4 PP</span></span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span><span>EBIT</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>7.6%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>8.5%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>3.1%</span></span></p></td><td style="vertical-align: bottom;"><p> </p></td><td style="vertical-align: bottom;"><p><span><span>8.6%</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>(0.1 PP)</span></span></p></td><td style="vertical-align: bottom;"><p><span><span>1.5 PP</span></span></p></td></tr></tbody></table><p> </p><p><strong>Basel, 19 August 2025: Medartis Holding AG (MED:SW), </strong><strong>a leading orthopaedic company specialising in head and extremity surgery, </strong><strong>today </strong><strong>reported total sales of CHF</strong><strong> </strong><strong>123.0</strong><strong> </strong><strong>million for H1 2025, representing growth of 14.1% at constant exchange rates (CER). Core sales reached CHF</strong><strong> </strong><strong>122.1</strong><strong> </strong><strong>million with organic growth of </strong><strong>15.3%. EMEA and US operations were key growth drivers, with both regions growing 16%. </strong><strong>Following this satisfying topline performance in H1, the Medartis management raises its sales guidance for the full-year. </strong></p><p> </p><p><strong>Matthias Schupp, CEO of Medartis,</strong> comments on the H1 result: "We delivered on our H1 commitments, giving us confidence in our outlook for the remainder of the year. My focus as CEO over the past nine months has been to strengthen our competitive positioning in the US and LATAM, and to finalise partnerships with NeoOrtho and KeriMedical that will serve as significant growth catalysts beyond 2025. We have also strengthened our R&D team to accelerate internal innovation. The cultural transformation is showing early positive signs—our US team has regained confidence, demonstrating a shift in attitude and adopted a more focused approach, with the new management making difficult yet necessary decisions to create an effective sales channel centred on the Medartis brand.”</p><p> </p><p> </p><p><strong>PERFORMANCE BY REGION</strong></p><p><strong> </strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: top;"><p><span><span>Core sales<sup>1</sup> in<br/> CHF million</span></span></p></td><td style="vertical-align: top;"><p><span><span>H1 2025</span></span></p></td><td style="vertical-align: top;"><p><span><span>H1 2024</span></span></p></td><td style="vertical-align: top;"><p><span><span>Organic growth<sup>2</sup><br/> in CHF</span></span></p></td><td style="vertical-align: top;"><p><span><span>Organic growth<sup>2</sup><br/> at CER</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>EMEA</span></span></p></td><td style="vertical-align: middle;"><p><span><span>67.9</span></span></p></td><td style="vertical-align: middle;"><p><span><span>59.5</span></span></p></td><td style="vertical-align: middle;"><p><span><span>14.1%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>16.0%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>US</span></span></p></td><td style="vertical-align: middle;"><p><span><span>26.1</span></span></p></td><td style="vertical-align: middle;"><p><span><span>23.2</span></span></p></td><td style="vertical-align: middle;"><p><span><span>12.7%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>16.2%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>APAC</span></span></p></td><td style="vertical-align: middle;"><p><span><span>17.1</span></span></p></td><td style="vertical-align: middle;"><p><span><span>15.6</span></span></p></td><td style="vertical-align: middle;"><p><span><span>9.7%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>14.9%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>LATAM</span></span></p></td><td style="vertical-align: middle;"><p><span><span>11.0</span></span></p></td><td style="vertical-align: middle;"><p><span><span>9.4</span></span></p></td><td style="vertical-align: middle;"><p><span><span>-5.7%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>8.2%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>Total Group</span></span></p></td><td style="vertical-align: middle;"><p><span><span>122.1</span></span></p></td><td style="vertical-align: middle;"><p><span><span>107.6</span></span></p></td><td style="vertical-align: middle;"><p><span><span>11.4%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>15.3%</span></span></p></td></tr><tr><td colspan="5" style="vertical-align: middle;"><p><span><span><sup>1</sup> Core sales excl. the NSI contract manufacturing business</span></span></p></td></tr><tr><td colspan="5" style="vertical-align: middle;"><p><span><span><sup>2</sup> Organic growth excl. the NeoOrtho business in LATAM, which has been consolidated since May 2025</span></span></p></td></tr></tbody></table><p> </p><p> In H1 2025, Medartis continued to demonstrate strong growth across its largest region, <strong>EMEA</strong>, achieving a 16.0% increase (CER) in sales to CHF 67.9 million. The UK and Spain were the standout performers in H1. The UK further benefited from strong wrist sales and a surging demand for KeriMedical products, whilst Spain delivered its fifth consecutive year of dynamic growth since the transition to direct sales. France showed a significant improvement driven by strong lower limb sales and benefiting from organisational changes implemented in 2024. Performance in the DACH countries was positive despite fewer trauma cases due to the relatively mild winter conditions. Distributor sales expanded at double-digit rates, supported by tender gains in the Middle East region and share gains in Italy.</p><p> </p><p> Both lower and upper extremities segments in EMEA advanced in the double-digit range. KeriMedical maintained its strong momentum and contributed a quarter to overall growth. The TOUCH franchise benefited from additional surgeon onboarding through train-and-use programmes as well as increased procedure volumes among existing users. Arthroplasty gains strong momentum as surgeons recognise advantages over traditional treatment methods, which require the sacrifice of the trapezium bone. Following an initial observation period, top users in Germany are now performing up to 200 procedures annually. In 2025, the TOUCH Dual Mobility prosthesis from KeriMedical achieved a prestigious ODEP rating from the Orthopaedic Data Evaluation Panel (ODEP), signifying the availability of more than 5 years of published clinical evidence. The TOUCH prosthesis is the only dual mobility CMCJ prosthesis with an ODEP rating<span><sup>[3]</sup></span>.</p><p> </p><p> The company made further investments in its digital offering CMX, which management considers mission-critical for the future. What initially began with digital case planning in head surgery is now available across all segments where Medartis operates. The company is also progressively expanding beyond case planning and surgical templates to include patient-specific solutions.<span></span></p><p><strong> </strong></p><p><strong>Medartis records double-digit US growth and strengthens elbow portfolio</strong></p><p> Medartis' core business in the<strong> US</strong> achieved growth of 16.2% (CER) with sales reaching CHF 26.1 million in H1 2025 (PY: CHF 23.2 million), securing additional market share. The declining US contract manufacturing business contributed an additional CHF 1.0 million in sales (PY: CHF 3.9 million). Performance was evenly distributed across product segments.</p><p> </p><p> The comprehensive review of the company's 57 distribution partners and necessary restructuring was completed in H1 2025, resulting in the discontinuation of 20 distributors. Most affected territories have since been reassigned, with the training department actively onboarding new distribution partners. All remaining distributors now operate under exclusive agreements with Medartis. To support new partnerships, the company has expanded its coverage by establishing a sixth sales region in the South East. Whilst management anticipates July and August will be required to complete the onboarding of its new distribution partners in Florida, performance acceleration is expected to materialise in the latter half of the year. The company strengthened its elbow portfolio during H1 with the launch of the Avenger radial head prosthesis and the dorsal olecranon plate. The next-generation Hand system, which has already been launched successfully in EMEA, is scheduled for launch in Q3.</p><p> </p><p> Following FDA approval of KeriMedical's TOUCH prosthesis on 10 July, the company has undertaken strategic preparations for its controlled market introduction. During H1, Medartis appointed a commercial director, recruited five clinical specialists, and expanded its education team. As part of the phased go-to-market strategy, 45 key opinion leaders (KOLs) designated to serve as peer-to-peer trainers are scheduled to perform their initial procedures in September. Distributed across 30 reference centres, these senior surgeons will gain experience before training their peers in H2 2026.</p><p> </p><p><strong>PERFORMANCE BY PRODUCT CATEGORY</strong></p><p> </p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: top;"><p><span><span>Core sales<sup>1</sup> in<br/> CHF million</span></span></p></td><td style="vertical-align: top;"><p><span><span>H1 2025</span></span></p></td><td style="vertical-align: top;"><p><span><span>H1 2024</span></span></p></td><td style="vertical-align: top;"><p><span><span>Organic growth<sup>2</sup><br/> in CHF</span></span></p></td><td style="vertical-align: top;"><p><span><span>Organic growth<sup>2</sup><br/> at CER</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>Upper Extremities</span></span></p></td><td style="vertical-align: middle;"><p><span><span>81.9</span></span></p></td><td style="vertical-align: middle;"><p><span><span>73.2</span></span></p></td><td style="vertical-align: middle;"><p><span><span>12.0%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>15.8%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>Lower Extremities</span></span></p></td><td style="vertical-align: middle;"><p><span><span>22.5</span></span></p></td><td style="vertical-align: middle;"><p><span><span>19.9</span></span></p></td><td style="vertical-align: middle;"><p><span><span>13.2%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>16.8%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>CMF and Others</span></span></p></td><td style="vertical-align: middle;"><p><span><span>17.7</span></span></p></td><td style="vertical-align: middle;"><p><span><span>14.6</span></span></p></td><td style="vertical-align: middle;"><p><span><span>6.2%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>10.3%</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>Total Group</span></span></p></td><td style="vertical-align: middle;"><p><span><span>122.1</span></span></p></td><td style="vertical-align: middle;"><p><span><span>107.6</span></span></p></td><td style="vertical-align: middle;"><p><span><span>11.4%</span></span></p></td><td style="vertical-align: middle;"><p><span><span>15.3%</span></span></p></td></tr><tr><td colspan="5" style="vertical-align: middle;"><p><span><span><sup>1</sup> Core sales excl. the NSI contract manufacturing business</span></span></p></td></tr><tr><td colspan="5" style="vertical-align: middle;"><p><span><span><sup>2</sup> Organic growth excl. the NeoOrtho business, which has been consolidated since May 2025</span></span></p></td></tr></tbody></table><p> </p><p> The <strong>APAC region </strong>delivered a strong start to H1 2025, with sales increasing 14.9% at CER to reach CHF 17.1 million. The largest country, Australia, achieved 10% volume growth driven by good momentum in wrist products and initial sales of the TOUCH prosthesis. However, revenue growth in Australia was constrained to 2% by government-mandated healthcare price reductions; this three-year deflationary cycle concluded in July. The company continues to gather clinical evidence demonstrating the product's medical advantages and strong health economic value proposition to secure appropriate reimbursement levels for this advanced solution. H2 will see the commercial launch of KeriFlex, which has obtained regulatory approval recently, alongside the introduction of the new Medartis hand system and the Dorsal Olecranon plate systems for elbow applications.</p><p> </p><p> The Japanese business showed strong growth in its CMF distribution business, whilst completing the transition to direct sales for upper extremities, establishing a dedicated and growing sales team. Building key opinion leader relationships and new customer acquisition represent the primary focus areas for the dedicated team. Performance in New Zealand and ASEAN markets progressed according to plan. The company benefited from working capital investment by the new distributor in New Zealand.</p><p><strong> </strong></p><p><strong>Negative trend in Brazil successfully reversed in H1 2025</strong></p><p> The<strong> LATAM </strong>business reported organic growth of 8.2% (CER) in H1, with organic sales reaching CHF 8.8 million. Growth would have been more pronounced without the significant depreciation of the Brazilian Real against the Swiss Franc (-13.9%). The NeoOrtho business, consolidated since May, contributed an additional CHF 2.2 million, bringing core sales to CHF 11.0 million. The company successfully reversed the negative trend of the past 18 months, returning to growth in the premium Medartis business. Since the completion of the NeoOrtho acquisition, the company has been implementing an integration plan to consolidate back-office functions and establish a new production facility in Curitiba, Brazil, scheduled for completion in early 2026. The premium and value brands will remain separate whilst exploiting cost synergies. The robust growth of NeoOrtho demonstrates the opportunities the company identifies in this market segment. In H1, NeoOrtho achieved the strongest growth in CMF, where premium players have encountered challenges in recent periods due to changes in insurance reimbursement policies. In response to the evolving regulatory landscape, the company has adapted its premium market approach, adjusted its pricing strategy and plans to commence sales of the CMF Modus 2 system in August following reapplication for market approval.</p><p><strong>FINANCIAL PERFORMANCE</strong></p><p><strong> </strong></p><p> This media release and other investor and financial press communications include Alternative Performance Measures (APMs). The Medartis management uses these metrics to assess Medartis' financial and operational performance, providing a complementary perspective to standard financial figures as defined by IFRS. These APMs exclude one-time effects and intangible asset amortization from M&A projects that could distort understanding of the company's ongoing operating performance. To arrive at the core result for H1 2025, the IFRS results exclude transaction costs of CHF 0.4 million (G&A) related to the NeoOrtho and KeriMedical acquisitions, as well as a negative contribution of CHF 0.7 million (Gross profit) from the US custom manufacturing business, which is scheduled for phase-out in the future. The following comments compare the core results for H1 2025 with those of the prior year period.</p><p> </p><p> Core <strong>gross profit </strong>in H1 2025<strong></strong> moderated 2.7PP (2.1PP at CER) and reached 80.7%, impacted by several factors:<span></span> Swiss franc appreciation and higher US tariffs each reduced margins by 0.5PP. To mitigate future tariff-related margin pressure, the company has deployed targeted countermeasures. The company has accelerated the Warsaw facility production ramp-up, which started in late 2024 and accelerated in April following the introduction of the new US tariffs, targets to produce 60% of US volume by end-2026 and 80% by mid-2027. NeoOrtho's value business proved modestly dilutive to group performance, reducing margins by 0.3 percentage points. KeriMedical distribution contracts currently remain dilutive for Medartis as a reseller of the TOUCH prosthesis (-0.8 percentage points), though this impact will fade in August following consolidation at full gross margin. The company's main production facility in Basel achieved further efficiency gains, contributing positively to overall group gross margin.</p><p> </p><p><strong>Operating expenses (OPEX)</strong> increased in absolute terms from CHF 81.3 million to CHF 89.1 million, reflecting the company's geographical expansion as well as the inclusion of the NeoOrtho business in H1 2025. However, OPEX as a percentage of sales decreased slightly from 72.9% in H1 2024 to 72.4% in the current period, demonstrating operational leverage despite higher absolute spending. In 2025, the company invested primarily in sales, marketing and medical education programmes. Distribution costs as a percentage of sales decreased slightly from 48.3% in H1 2024 to 46.0% in the current period. General administration expenses increased to CHF 19.4 million or 15.7% as a percentage of sales. The share of the results from the associated company KeriMedical rose marginally to CHF 1.0 million.</p><p> </p><p> Despite the lower gross margin, disciplined cost management helped improve core <strong>EBITDA</strong>, which increased from CHF 19.1 million in the prior year period to CHF 21.7 million in H1 2025. The respective EBITDA margin remained flat at 17.8% and the core <strong>EBIT</strong> margin also remained stable at 8.5%, matching the prior year's level. Excluding adverse currency impacts, both EBITDA and EBIT margins would have expanded by 1.4 or 1.5 percentage points, respectively.</p><p> </p><p> The core <strong>net result</strong> decreased from a profit of CHF 7.3 million in H1 2024 to a small loss of CHF ‑0.4 million in H1 2025, primarily due to foreign exchange losses (USD and AUD) of CHF 5.0 million and financing costs of CHF 3.2 million related to the convertible bonds launched in April 2024. <strong>Operating cash flow</strong> decreased by CHF 0.7 million to CHF 8.6 million, and <strong>free cash flow</strong> reached CHF 0.4 million after deducting slightly higher CAPEX expenditure of CHF -8.2 million. This includes new production machinery for the company's US facility. M&A investments totalled CHF ‑12.6 million in H1 2025, reflecting the acquisition of a controlling 51% interest in NeoOrtho. At the end of June, the company's <strong>cash position</strong> stood at CHF 120.5 million, a large portion of which will be used to finance the share purchase of the remaining 53% stake in KeriMedical, as previously announced. For further information on the company’s financials, please review the <span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8HdhaRchmqbBiqaO6Ma9ZMnYVNbpeLapapbOn9aO6NmBaQ8B0Lx2MEmp0ovkTJlpA/dh6McYiPah3BxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '50865955');" class='js-l-obf link link--blue'><span><u>2025 half-year report</u></span></span>.</p><p><strong> </strong></p><p><strong>FULL-YEAR 2025 OUTLOOK</strong></p><p><span style="text-transform: uppercase;">(barring any unforeseen circumstances)</span></p><p><strong> </strong></p><p> Medartis expects to strengthen its market position in the US in 2025, while making gradual progress in Japan, LATAM and Australia. Following the satisfying topline performance in H1, the company increased its full-year sales guidance and now expects organic growth in core sales<span><sup>[4]</sup></span><span><sup>4</sup></span> of 14-16%. The company reiterates its core EBITDA margin target in the high-teens. Since the announcement of US reciprocal tariffs on 2 April, the company has developed several mitigation actions to absorb the financial impact of these additional costs.</p><p><strong> </strong></p><p><strong>____________________________________________________________________________________</strong></p><p><strong> </strong></p><p><span style="text-transform: uppercase;"><strong>Medartis to Host HALF-Year 2025 Results Conference CALL with</strong></span><span style="text-transform: uppercase;"><strong>Q&A</strong></span></p><p><span>Medartis will present its half-year 2025 results today at 09:30 a.m. CEST at a online webcast. The CEO, Matthias Schupp, and CFO, Dirk Kirsten, will host the event. The conference will be held in English. The presentation slides, H1 Financial Report and a recording of the event is available on the Medartis website (</span><span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8HdkeMmBeLbO6paO3qbOVRaOmMmBfBnYiNmhW5b9ZQaO5/8B0Lx2MEmp0ovkTJlpA/dh6McYiPah3BxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '50865955');" class='js-l-obf link link--blue'><span><u>medartis.com</u></span></span><span>).</span></p><p> </p><p> Kindly use the <span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8Hdk6pahnAchmqakb7nYnBb9mMckbAaOfAah05ck07ah3Q8B0Lx2MEmp0ovkTJlpA/dh6McYiPah3BxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '50865955');" class='js-l-obf link link--blue'><span><u>webcast link</u></span></span> to follow the slide presentation and submit questions in writing or via the webcast.</p><p><strong> </strong></p><p><br/><strong>IMPORTANT DATES AND UPCOMING INVESTOR EVENTS</strong><br/> </p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: top;"><p><span><span>Date</span></span></p></td><td style="vertical-align: top;"><p><span><span>Event</span></span></p></td><td style="vertical-align: top;"><p><span><span>Broker</span></span></p></td><td style="vertical-align: top;"><p><span><span>Destination</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>19 August</span></span></p></td><td style="vertical-align: middle;"><p><span><span>2025 first-half results publication</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p><span><span>Online</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>20 August</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Non-deal roadshow</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Octavian</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Frankfurt</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>21 August</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Non-deal roadshow</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Octavian</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Zurich</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>17 September</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Non-deal roadshow</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Bank of America</span></span></p></td><td style="vertical-align: middle;"><p><span><span>London</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>18 September</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Convertible conference</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Bank of America</span></span></p></td><td style="vertical-align: middle;"><p><span><span>London</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>06 November</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Swiss Equities conference</span></span></p></td><td style="vertical-align: middle;"><p><span><span>ZKB</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Zurich</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>11 November</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Healthcare conference</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Stifel</span></span></p></td><td style="vertical-align: middle;"><p><span><span>New York</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>12 November</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Non-deal roadshow</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Stifel</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Chicago</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>18 November</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Non-deal roadshow</span></span></p></td><td style="vertical-align: middle;"><p><span><span>UBS</span></span></p></td><td style="vertical-align: middle;"><p><span><span>London</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>19 November</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Healthcare conference</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Jefferies</span></span></p></td><td style="vertical-align: middle;"><p><span><span>London</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span><strong>2026</strong></span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>17 March</span></span></p></td><td style="vertical-align: middle;"><p><span><span>2025 full-year results publication</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p><span><span>Basel, HQ</span></span></p></td></tr><tr><td style="vertical-align: middle;"><p><span><span>23 April</span></span></p></td><td style="vertical-align: middle;"><p><span><span>Annual General Meeting 2026</span></span></p></td><td style="vertical-align: middle;"><p> </p></td><td style="vertical-align: middle;"><p> </p></td></tr></tbody></table><p><strong> </strong></p><p><strong> </strong></p><p><span><strong>Your contact:</strong></span></p><p><span>Medartis Corporate Communications</span></p><p><span>Fabian Hildbrand, Head of Corporate Communications, investor.relations@medartis.com</span></p><p><span>Andreas Richter, Corporate Communications Manager, corporate.communication@medartis.com</span></p><p><span>+41 61 633 37 36 / +41 61 633 37 34</span><br/> </p><p> </p><p><span><strong>About Medartis</strong></span></p><p><span>Founded in 1997 and headquartered in Basel, Switzerland, the Medartis Group is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 1’160 individuals across its 13 locations, with products offered in over<br/> 50 countries globally. The company has its main production facility in Basel, Switzerland, with additional production centres in Warsaw, USA, Curitiba, Brazil, and Archamps and Besançon, France. Medartis is committed to providing surgeons and<br/> operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service.<br/> For more information, please visit <span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8Hdk6PmOiOmBmRm9mOa9aqn2fAbOA7mk6omBZoaOj9mk0A8B0Lx2MEmp0ovkTJlpA/dh6McYiPah3BxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '50865955');" class='js-l-obf link link--blue'><span><u>www.medartis.com</u></span></span>.</span></p><p> </p><p> </p><p><span><strong>Disclaimer</strong></span></p><p><span>This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Furthermore, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or of the views given or implied, and accordingly no reliance should be placed thereon.</span></p><p> </p><p> </p></div><hr style="width: 33%;"/><div id="_ftn1"><p><span><span><sup>1</sup></span> Organic growth excludes the effects of mergers and acquisitions (e.g. NeoOrtho in H1 2025) and, unless otherwise stated, reported at constant exchange rates (CER).</span></p></div><div id="_ftn2"><p><span><span><sup>2</sup></span> This media release and accompanying financial documents include alternative performance measures (APMs), referred to as 'core' figures. Core figures exclude certain one-time, non-recurring and extraordinary items or items related to M&A that distort the understanding of the company's underlying performance. Additionally, the US contract manufacturing business (former NSI) is classified as non-strategic and therefore excluded from core figures. For a detailed overview of all non-core events, please refer to the APM section in the “2025 Half-year report” on p. 7.</span></p></div><div id="_ftn3"><p><span><span><sup>3</sup></span> Latest ODEP ratings can be found at www.odep.org.uk</span></p></div><div id="_ftn4"><p><span><span><sup>4 </sup></span>Core revenue growth measured at CER achieved through existing operations, i.e. excluding growth from M&A.</span></p></div></div><div markup="contact"><p><strong><span><span><span>Postal address:</span></span></span></strong></p><p><span><span><span>Medartis Holding AG<br/> Hochbergerstrasse 60E<br/> CH-4057 Basel</span></span></span></p></div></div><br/><hr/>End of Inside Information<hr/></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" nowrap="nowrap">Language:</td><td align="left" valign="top"> English</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Company:</td><td align="left" valign="top"> Medartis Holding AG </td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"> Hochbergerstrasse 60E</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"> 4057 Basel</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"> Switzerland</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Phone:</td><td align="left" valign="top"> +41 61 633 34 34</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Fax:</td><td align="left" valign="top"> +41 61 633 34 00</td></tr><tr><td align="left" valign="top" nowrap="nowrap">E-mail:</td><td align="left" valign="top"> info@medartis.com</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Internet:</td><td align="left" valign="top"> www.medartis.com</td></tr><tr><td align="left" valign="top" nowrap="nowrap">ISIN:</td><td align="left" valign="top"> CH0386200239</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Valor:</td><td align="left" valign="top"> 38620023</td></tr><tr><td align="left" valign="top">Listed:</td><td align="left" valign="top"> SIX Swiss Exchange</td></tr><tr><td align="left" valign="top" nowrap="nowrap">EQS News ID:</td><td align="left" valign="top"> 2185518</td></tr></table><br/><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"/></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"> </td></tr><tr><td align="left" valign="top">End of Announcement</td><td align="left" valign="top"> EQS News Service</td></tr></table><table border="0" width="600" cellpadding="0" cellspacing="0"><tr><td><hr/></td></tr></table><p> 2185518 19-Aug-2025 CET/CEST </p><img data-zoomable="true" src="https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2185518&application_name=news&site_id=zonebourse_com~~~71435185-72e2-4ff3-98c0-1866a1714c4a" alt="" width="0" height="0" border="0"/></p></div><div class="grid gbetween align-center mt-15"><div class="c-auto mb-15 txt-s2"><div></div> © EQS - 2025 </div><div class="c-auto mb-15"><div class="dropdown-container "><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#shareIt_88260" ><span class="px-15 py-10 btn btn--action--outter c-block"><i class="bi-box-arrow-up"></i> Share </span></span><div id="shareIt_88260" class="dropdown "><div class="py-10 px-15"><div class="grid gnowrap" data-trans="Link copied"><a class="c-block c " target="popup" style="color:#0073b1" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year&summary=Medartis Holding AG / Key word: Half Year Results Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year 19-Aug-2025 / 06:59 CET/CEST Release of an ad hoc...&source=" title="Share on LinkedIn" rel="nofollow" https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year&summary=Medartis Holding AG / Key word: Half Year Results Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year 19-Aug-2025 / 06:59 CET/CEST Release of an ad hoc...&source=','popup','width=600,height=600'); return false;" ><i class="bi-linkedin txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#000" href="https://x.com/intent/tweet?text=Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year%20%23MarketScreener&url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dtwitter%26utm_medium%3Dsocial%26utm_campaign%3Dshare" title="Share on X" rel="nofollow" https://x.com/intent/tweet?text=Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year%20%23MarketScreener&url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dtwitter%26utm_medium%3Dsocial%26utm_campaign%3Dshare','popup','width=600,height=600'); return false;" ><i class="bi-twitter-x txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#25D366" href="https://wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare" title="Share on WhatsApp" rel="nofollow" ><i class="bi-whatsapp txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#0088cc" href="https://telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare" title="Share on Telegram" rel="nofollow" ><i class="bi-telegram txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#1877f2" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare" title="Share on Facebook" rel="nofollow" https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare','popup','width=600,height=600'); return false;" ><i class="bi-facebook txt-s4 px-5"></i></a><a class="c-block c js-copyArticle" target="popup" style="color:#3a3a3a" href="https://www.marketscreener.com/news/medartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221?utm_source=copy&utm_medium=social&utm_campaign=share" title="Share on Copy" rel="nofollow" ><i class="bi-link-45deg txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#3a3a3a" href="mailto:?subject=MarketScreener.com: Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year&body=Medartis delivers 15.3%25 organic sales growth in H1 and lifts sales guidance for the full-year%0D%0A%0D%0AMedartis Holding AG / Key word: Half Year Results Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year 19-Aug-2025 / 06:59 CET/CEST Release of an ad hoc...%0D%0A%0D%0Ahttps%3A%2F%2Fwww.marketscreener.com%2Fnews%2Fmedartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221%3Futm_source%3Demail%26utm_medium%3Dsocial%26utm_campaign%3Dshare" title="Share on Email" rel="nofollow" ><i class="bi-envelope-fill txt-s4 px-5"></i></a></div></div></div></div></div></div></article></div></div><div class="m-15" id="Zonebourse_Article_Video"><div class="vsly-player media--169 bg-grey position-relative" id="PLCHkFhqLGmYn" data-template="PVaRF_MsC2XGj"></div></div><div class="mb-15 gcenter"><div class='zppAds'><div id='zppVideoAnchor'></div></div><script> aAdsList.push('VideoAnchor'); aAdsListSize.push(null); aAdsListCA.push(['US']); </script></div><div class="card mb-15"><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/"> Latest news about Medartis Holding AG </a></h3></div><div class="card-content"><table class="table table--small table--hover table--bordered"><tbody><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-05-13T22:00:00+00:00" title="06:00:00 2026-05-13 pm EDT"> May. 13</span></td><td class="w-100"><a href="/news/medartis-holding-ag-completed-the-acquisition-of-cadskills-bv-ce7f5adfdb8cf120" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG completed the acquisition of Cadskills Bv. </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-04-23T13:00:00+00:00" title="09:00:00 2026-04-23 am EDT"> Apr. 23</span></td><td class="w-100"><a href="/news/medartis-holding-ag-elects-yang-xu-as-board-director-and-member-of-finance-and-audit-committee-ce7f59ded080f020" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG Elects Yang Xu as Board Director and Member of Finance and Audit Committee </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-04-17T13:56:00+00:00" title="09:56:00 2026-04-17 am EDT"> Apr. 17</span></td><td class="w-100"><a href="/news/straumann-holding-ag-announces-board-changes-ce7f59d9de8afe2c" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Straumann Holding AG Announces Board Changes </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-17T15:09:00+00:00" title="11:09:00 2026-03-17 am EDT"> Mar. 17</span></td><td class="w-100"><a href="/news/medartis-holding-ag-reports-earnings-results-for-the-full-year-ended-december-31-2025-ce7e5ed8df8ff021" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG Reports Earnings Results for the Full Year Ended December 31, 2025 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-17T11:35:59+00:00" title="07:35:59 2026-03-17 am EDT"> Mar. 17</span></td><td class="w-100"><a href="/news/transcript-medartis-holding-ag-2025-earnings-call-mar-17-2026-ce7e5edbdf8fff20" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG, 2025 Earnings Call, Mar 17, 2026 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"><i class="bi-mic-fill txt-negative"></i></span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-17T06:25:18+00:00" title="02:25:18 2026-03-17 am EDT"> Mar. 17</span></td><td class="w-100"><a href="/news/medartis-logs-higher-fy25-net-income-revenue-ce7e5edbda8afe25" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Logs Higher FY25 Net Income, Revenue </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MT Newswires"><span class="c-inline txt-align-center" style="width: 18px;"> MT </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-17T05:52:43+00:00" title="01:52:43 2026-03-17 am EDT"> Mar. 17</span></td><td class="w-100"><a href="/news/swiss-stocks-factors-to-watch-on-march-17-ce7e5edbda89ff25" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Swiss stocks - Factors to watch on March 17 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;"> RE </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-17T05:33:24+00:00" title="01:33:24 2026-03-17 am EDT"> Mar. 17</span></td><td class="w-100"><a href="/news/medartis-builds-on-momentum-with-16-organic-sales-growth-and-core-ebitda-margin-exceeding-18-ce7e5edbdb80ff2c" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis 2025 organic core sales grow 15.7% to CHF 266.1 million </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;"> RE </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2026-03-16T23:00:00+00:00" title="07:00:00 2026-03-16 pm EDT"> Mar. 16</span></td><td class="w-100"><a href="/news/medartis-holding-ag-signed-a-definitive-agreement-to-acquire-cadskills-bv-ce7f5adfdb8cf025" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG signed a definitive agreement to acquire Cadskills Bv. </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-11-24T06:54:35+00:00" title="01:54:35 2025-11-24 am EST"> Nov. 24</span></td><td class="w-100"><a href="/news/medartis-names-new-finance-chief-ce7d5edcda8cf12d" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Names New Finance Chief </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MT Newswires"><span class="c-inline txt-align-center" style="width: 18px;"> MT </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-11-24T06:02:35+00:00" title="01:02:35 2025-11-24 am EST"> Nov. 24</span></td><td class="w-100"><a href="/news/medartis-appoints-peter-hackel-as-new-chief-financial-officer-ce7d5edcda8bf620" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis appoints Peter Hackel as new chief financial officer </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;"> RE </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-11-23T23:00:00+00:00" title="06:00:00 2025-11-23 pm EST"> Nov. 23</span></td><td class="w-100"><a href="/news/medartis-holding-ag-announces-cfo-changes-ce7d51dade8df426" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG Announces CFO Changes </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-08-19T21:21:58+00:00" title="05:21:58 2025-08-19 pm EDT"> 25-08-19</span></td><td class="w-100"><a href="/news/medartis-holding-ag-reports-earnings-results-for-the-half-year-ended-june-30-2025-ce7c51ddde8af226" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG Reports Earnings Results for the Half Year Ended June 30, 2025 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"> CI </span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-08-19T09:20:16+00:00" title="05:20:16 2025-08-19 am EDT"> 25-08-19</span></td><td class="w-100"><a href="/news/transcript-medartis-holding-ag-h1-2025-earnings-call-aug-19-2025-ce7c51dcd080fe26" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Medartis Holding AG, H1 2025 Earnings Call, Aug 19, 2025 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"><i class="bi-mic-fill txt-negative"></i></span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5" data-utc-date="2025-08-19T07:43:14+00:00" title="03:43:14 2025-08-19 am EDT"> 25-08-19</span></td><td class="w-100"><a href="/news/corporate-results-schedule-for-august-19-2025-ce7c51dcd08bff22" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 "> Corporate results schedule for August 19, 2025 </a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MarketScreener.com"><span class="c-inline txt-align-center" style="width: 18px;"><img src="https://cdn.zonebourse.com/images/logo_at.gif" width="14" height="8" alt="Zonebourse"></span></span></td></tr></tbody></table></div></div></div><div class="c-12 cm-4 "><div class="card mb-15"><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/graphics/"> Chart Medartis Holding AG </a></h3></div><div class="card-content"><div class="grid mb-15"><div class="c-auto "><label for="bWCMois">Duration</label><selectchart_ta_42470802','duration',this.value)" id="bWCMois" class="ml-5 input"><option value="8" selected>Auto.</option><option value="2">2 months</option><option value="3">3 months</option><option value="6">6 months</option><option value="9">9 months</option><option value="12">1 year</option><option value="24">2 years</option><option value="60">5 years</option><option value="120">10 years</option><option value="9999">Max.</option></select></div><div class="c-auto "><label for="bWCPer">Period</label><selectchart_ta_42470802','cycle',this.value)" id="bWCPer" class="ml-5 input"><option value="DAY" selected>Day</option><option value="WEEK">Week</option></select></div></div><div class="txt-align-center media media--43 placeholder placeholder--w"><img id="chart_ta_42470802" data-src="https://www.marketscreener.com/zbcache/charts/ObjectChart.aspx?Name=42470802&Type=Custom&Intraday=1&Width={width}&Height={height}&Cycle=DAY1&Duration={duration}&Render=Candle&ShowCopyright=2&ShowName=0&Locale=en&ShowVolume=1&Company=Skin:ZonebourseLight&externload=" src="data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=" data-cycle="DAY1" data-type="1" alt="Chart Medartis Holding AG" class="c-block js-responsive-ta-chart" /></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/graphics/" class="more"> MED: Dynamic Chart </a></div></div><div id="companyProfile" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="companyProfile"></span><div class="card-header"><h2 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/company/"> Company Profile </a></h2></div><div class="card-content"><div><div class="mb-10 txt-justify txt-overflow-6"><div style="float:left;" class="mr-10"><img height="30" alt="Logo Medartis Holding AG" none'" src="https://cdn.zonebourse.com/static/instruments-squared-42470802.png" ></div> Medartis Holding AG is a Switzerland-based holding company of the Medartis Group, which is engaged in manufacturing medical devices and implants. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. It has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors. </div><div class="grid pb-10 pb-m-5 border-top pt-5"><div class="c-3 txt-bold">Employees</div><div class="c-9 txt-align-right"> 1,259 </div></div><div class="grid py-10 py-m-5 border-top txt"><div class="c-3 txt-bold">Sector</div><a class="c-9 txt-align-right link" href="/stock-exchange/sectors/healthcare/healthcare-services/?cf=ME5wTzZia2NKbTZkdlhjdDhhdGtyb1pnVFY4WDdvSjR6R0poRWdmMzg3bz0"> Medical Equipment, Supplies & Distribution </a></div><div class="grid py-10 py-m-5 border-top txt"><div class="c-3 txt-bold">Calendar</div><div class="c-9 txt-align-right txt-inline"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/calendar/" class="link"> Earnings release - Q2 2026 </a></div></div></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/company/" class="more"> More about the company </a></div></div><div id="chart_right_ise_e_card" class="card card--collapsible mb-15 pos-next"><span class="js-collapse collapse" data-collapse="chart_right_ise_e_card"></span><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/finances/"> Income Statement and Estimates </a></h3></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='250' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/finances/" class="more"> More financial data </a></div></div><div id="ratings" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="ratings"></span><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/ratings/"> Ratings </a></h3></div><div class="card-content"><div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Trader </div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4057" data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4057" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Trader</p><p>This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="12%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Investor </div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4058" data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4058" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Investor</p><p>This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="15%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Global </div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4049" data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4049" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Global</p><p>This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="8%" class="star star--size1 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Quality </div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4050" data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4050" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Quality</p><p>This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="16%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 "><div class="c"><i class="bi-star-half pr-5"></i>ESG MSCI </div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_5546" data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_5546" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">ESG MSCI</p><p>The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.</p></div></div></div></div><div class="c-f90 txt-align-center"><div class="esg-rank esg-rank--aa txt-bold txt-align-center">AA</div></div></div></div><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='320' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/ratings/" class="more">More Ratings</a></div></div><div id="consensusDetail" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="consensusDetail"></span><div class="card-header c-flex gbetween"><h2 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus/"> Analysts' Consensus </a></h2></div><div class="card-content"><div><div class="txt-align-center my-10">Sell<div class="consensus-gauge" title="Rate: 7.5 / 10"><img style="padding-left:68.5px;" src="https://cdn.zonebourse.com/images/consensus_flch.gif" alt="Consensus"></div>Buy</div><div class="grid py-5"><div class="c">Mean consensus</div><div class="c-auto txt-align-right txt-bold">OUTPERFORM</div></div><div class="grid border-top py-5"><div class="c">Number of Analysts</div><div class="c-auto txt-align-right txt-bold">4</div></div><div class="grid border-top py-5"><div class="c">Last Close Price</div><div class="c-auto txt-align-right txt-bold"><span class="last " >72.60</span>CHF</div></div><div class="grid border-top py-5"><div class="c">Average target price</div><div class="c-auto txt-align-right txt-bold"><span class="last " >95.97</span>CHF</div></div><div class="grid border-top py-5"><div class="c">Spread / Average Target</div><div class="c-auto txt-align-right txt-bold"><span class="variation variation--pos no-animation txt-align-center c-block " >+32.19%</span></div></div></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus/" class="more">Consensus</a></div></div><div id="chart_change_eps-cae" class="card card--collapsible mb-15 pos-next"><span class="js-collapse collapse" data-collapse="chart_change_eps-cae"></span><div class="card-header"><a class="card-title" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus-revisions/">EPS Estimates</a></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=NXlMWVoxUzNiUmVJZXhZSzZyemovWkVwSnk5SHI1RytCaUs1MXhaKzQxS0hzNWRqMzJrRlFKaXY5SE12NVNSd252VkpaTzc5dXl4eWwvVjB0UmxCWWpGV3phWUJHSnUxaHZ5K1ZWZEVLL1pPNXExL2dFWXpOZS9zQyttMlFST25iY2cwVFM4Y2E5L0hIM3M4cmNiUU9QTEo1UmZJSlJmRzN6cm8vVkpuVXkxQ0pHTGJ5NWg4blBxMTN1U21GRzZGVG1LYTJBU1FuR0dMdXBaY1d4T2dRRnQvdG15aUg3VFFPSGJpTVdNVGFxQ3hnQzFXcnhka1dMc1VDMWpJalJrdjFLRllhdFdzZHJzWGNNQlpMakVXcTZxTTlnTjNCZ28wK0k4M1lKQmF1aDA3cnRaVGxBcEgzc0JZZ1lxUkZCVUdRYnBqV01rWGFZMTFTd2c3SUdncm52R1Q4V01yU1BtUWE3NjJTamYyOFBLL2NNNjM2R25IMGNwODRCaGZpdm8vei9ydERzN25DaGI5MkNEVUtHd1IxUnZXNGp2R3RqNU90TnRyUzZBMHBQdz0" alt="" class='w-100' height='300' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a class="more" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus-revisions/"> Revisions to estimates </a></div></div><div id="chart_qual_est" class="card card--collapsible pos-next mb-15"><span class="js-collapse collapse" data-collapse="chart_qual_est"></span><div class="card-header"><h3 class="card-title">Quarterly revenue - Rate of surprise</h3></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='300' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a class="more" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/calendar/"> Company calendar </a></div></div></div></div><div class="mb-15 c-12 c-flex gcenter"><div class='zppAds'><div id='zppFooter'></div></div><script> aAdsList.push('Footer'); aAdsListSize.push([[970, 250], [1000, 180], [1000, 200], [1000, 250]]); aAdsListCA.push(null); </script></div></main><div class="js-responsive-move-container c-none cl-block" data-move-id="rs_light_screen_content"><div class="js-responsive-move h-100" data-move-id="rs_light_screen_content" data-move-type="large"><aside class="c-none cm-block cm-f300 pt-5 h-100"><div class="rsidebar" style="margin:0;" ><script> const RS_ASYNC = true; </script><div class="rsidebar__component rsidebar__indexes mt-10 mt-m-0"><div class="rsidebar__indexes__menu px-5"><span data-tab="0" class="c js_rs__link link link--white rsidebar__indexes__menu__row rsidebar__indexes__menu__row--active" ><i class="bi-activity"></i> Indices</span><span data-tab="1" class="c js_rs__link link link--white rsidebar__indexes__menu__row " > Europe</span><span data-tab="2" class="c js_rs__link link link--white rsidebar__indexes__menu__row " > America</span><span data-tab="3" class="c js_rs__link link link--white rsidebar__indexes__menu__row " > Asia</span></div><div class="rsidebar__indexes__container"><div class="rsidebar__indexes__container__tab rsidebar__indexes__container__tab--active"><div class="txt-align-center px-m-5 p-5 my-10 bg-graph-intra-dark" style="height:116.8px"><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div></div></div><div class="my-15"><div class='zppAds'><div id='zppRight2'></div></div><script> aAdsList.push('Right2'); aAdsListSize.push([300, 600]); aAdsListCA.push(null); </script></div><div id="rs-watchlist" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><a href="/watchlist" class="rsidebar__title mt-0 txt-white">My Watchlist</a><div class="c ml-15 js-rs-watchlist placeholder"> </div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div><a href="/watchlist" class="c-block pl-0 py-5 txt-s2 more">My lists</a></div><div id="rs-palmares-0" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><span class="rsidebar__title mt-0 txt-white placeholder">Rankings</span><div class="c ml-15 js-rs-watchlist placeholder"> </div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><div class="pt-5"><div class="chart chart--h150 placeholder bg-black-primary"></div></div></div><a href="#" class="c-block pl-0 py-5 txt-s2 more placeholder"> More Rankings </a></div><div id="rs-palmares-1" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><span class="rsidebar__title mt-0 txt-white placeholder">Rankings</span><div class="c ml-15 js-rs-watchlist placeholder"> </div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><div class="pt-5"><div class="chart chart--h150 placeholder bg-black-primary"></div></div></div><a href="#" class="c-block pl-0 py-5 txt-s2 more placeholder"> More Rankings </a></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Currency / Forex</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Commodities</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Cryptocurrencies</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Interest Rates</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div></aside></div></div></div><div class="bcrumb"><ol itemscope itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/" href="/"><span itemprop="name">Stock Market</span></a><meta itemprop="position" content="1"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/news/" href="/news/"><span itemprop="name">Stock Market News</span></a><meta itemprop="position" content="2"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><span itemprop="name">Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year</span><meta itemprop="position" content="3"></li></ol></div></div></div><footer><div class="container"><div class="grid gbetween align-center border-bottom--black mb-15 pb-15"><div class="pos-1 c c-none cs-block"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_portail.png" width="40" height="40" alt="Best financial portal" loading="lazy" /></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5"> Best financial<br/> portal </p></div><div class="pos-3 c-6 cxs"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_2001_en.png" width="40" height="40" alt="More than 20 yearsat your side" loading="lazy"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5"> More than 20 years<br/>at your side </p></div><div class="c-6 cxs pos-5"><div class="txt-align-center js-l-obf cursor-pointer" data-tobf='blank' data-lobf="v4fox4ar=NToxCjOy4WEw2To=BbKwgTNnlnEnlxKwk0NvpjoxpbNnkjJnl6JmpTIdQboml8Odhiu"><img src="https://cdn.zonebourse.com/static/resize/106/48//static/images/footer/img_footer_trustpilot_4.png" loading="lazy" width="106" height="48" alt="Trustpilot"/></div></div><div class="c-6 cxs pos-3 pos-xs-7 mb-25 mb-s-0"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_membresl.png" width="40" height="40" loading="lazy" alt="+ 1,300,000members"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5"> + 1,300,000<br/>members </p></div><div class="c c-none cs-block pos-6"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_resilitaion.png" width="40" height="40" loading="lazy" alt="Quick & easycancellation"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5"> Quick & easy<br/>cancellation </p></div><div class="c c-none cm-block pos-8"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_experts.png" width="40" height="40" loading="lazy" alt="Our Expertsare here for you" /></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5"> Our Experts<br/>are here for you </p></div></div><div class="grid my-15 py-10 align-center"><div class="c-12 cs mr-auto c-flex align-center gcenter gs-start"><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTq=BbKwgTbml8GnlfOmQ8AnkRAx9Zu"><i class="bi-twitter-x txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJzkTPy4j7ngR9wpoKeZP5xBIAy0b9xBjAwBjN"><i class="bi-youtube txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJvkROy20CxB0I=BbKwgTIml8GnlfOmQ8AnkRAxBTBnBA9vk0H=Luu"><i class="bi-instagram txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJw2AJvpj/vkqJmpTI=pbKwlW5wC/Kwk0NvpjoxpbNnkjJnl6K"><i class="bi-linkedin txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJy2AGy2TG=BbKwgTVwk0NvpjoxpbNnkjJnl6JmpTI"><i class="bi-tiktok txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer" data-tobf='blank' data-lobf="v4fox4ar=NT5x4WO=B0Lx2MA=BbKwgTPxNT5x4VKwk0NvpjoxpbNnkjJnl6KvkePbOeOcYxochxu"><img src="https://cdn.zonebourse.com/static/images/footer/img_footer_appstore.png" alt="Download from Apple Store" loading="lazy"/></span></div><div class="c-12 cs-auto my-25 my-s-0"><div class="c-flex txt-white txt-s2 align-center gcenter"><div class="c"><p class="m-0">OUR EXPERTS ARE HERE FOR YOU</p><p class="m-0 txt-bold" >Monday - Friday 9am-12pm / 2pm-6pm GMT + 1</p></div><div class="pl-10 c-auto"><span class="js_modal_button" data-modal="contact-us" style="cursor:pointer;"><span class="btn btn--footer">Contact us</span></span><div id="contact-us" class="modal modal--large modal--no-refresh " ><span class="js_modal_close modal__close-btn"contact-us')"><i class="bi-x txt-s6 txt-black"></i></span><div class="modal__content h-100"></div></div></div></div></div><div class="c ml-auto txt-align-center txt-align-s-right"><div class="p-m-15 pr-10"><span class="js-l-obf cursor-pointer" data-lobf="=Luu"><img src="https://cdn.zonebourse.com/static/images/footer/footer_logo_ms.png" width="218" height="21" alt="MarketScreener, Stock Market Live" loading="lazy"/><span></div></div></div><div class="grid gcenter txt-footer mt-30"><span class="js-l-obf cursor-pointer c-auto" data-tobf='blank' data-lobf="=pMAnp0H=kRKy2A9neuu"> Legal information </span><span class="c-none cs-inline ml-5 mr-5 c-auto">|</span><span class="cursor-pointer" show', 2, console.log, {jumpAt: 'privacy'});"> Cookie settings </span><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><span class="js-l-obf cursor-pointer c-auto" data-tobf='blank' data-lobf="=p8HwpxK"> MarketScreener Blog </span><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><a href="/about-us" class="link txt-footer"> About us </a><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><span class="c-block cs-inline txt-align-center" > Copyright © 2026 Surperformance SAS. All rights reserved. </span></div><div class="txt-align-center txt-footer mt-10"> Stock quotes are provided by Factset, Morningstar and S&P Capital IQ </div></div></footer><script data-action="javascript-global-variable"> const GLOBAL_LOCALE = "en_US"; const GLOBAL_LANG = "en"; const GLOBAL_ISMOBILE = false; const GLOBAL_TIMEZONE = "America/New_York" const GLOBAL_XID = "" const GLOBAL_ENV = 'PROD'; const GLOBAL_COLOR_SCHEME = 'light'; </script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js></script><script data-version='external' src=https://securepubads.g.doubleclick.net/tag/js/gpt.js></script><script data-version='external' id=xieg6Sie src=https://cdn.viously.com/js/sdk/boot.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/highstock.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/modules/treemap.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/modules/heatmap.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/highcharts-more.min.js></script><script data-version='external' src=https://cdn.appconsent.io/loader.js></script><script data-version='external' src=https://www.googletagmanager.com/gtag/js?id=G-W5MZBYLHSG></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/socket.io/4.8.1/socket.io.min.js></script><script data-version='external' src=https://accounts.google.com/gsi/client></script><script data-version='v1779441044' src="https://cdn.zonebourse.com/static/compiled-js/prod-1779441044-12250bd13a4782ac206952327ef0342d.min.js"></script><script> __tcfapi('init', 2, function() { __tcfapi('show', 2, console.log, {jumpAt: 'banner',lazy: true}); __tcfapi("addEventListener", 2, function (tcData, success) { if(success && tcData.eventStatus === 'tcloaded' && tcData.addtlConsent === null) { console.log("show CMP"); __tcfapi('show', 2, console.log); } } ); }, { appKey: '5eef9679-6e01-4486-8a2f-e0bdb1912916', urlRedirect: { main: { denyAll : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement', continueWithoutAccepting : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement', }, settings : { denyAll : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement', } }, } ) </script><script data-action="{} Tags init"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); function gaEvent(eventCategory, eventAction, eventLabel, eventValue) { var eventConf = {}; eventConf['send_to'] = 'G-W5MZBYLHSG'; if (typeof eventCategory !== 'undefined') eventConf['event_category'] = eventCategory; if (typeof eventLabel !== 'undefined') eventConf['event_label'] = eventLabel; if (typeof eventValue !== 'undefined') eventConf['value'] = eventValue; gtag('event',eventAction,eventConf); } </script><div id='div-gpt-ad-pixel' style="position:fixed;bottom:0;pointer-events: none"></div><script> googletag.cmd.push(()=>{ googletag.defineSlot('/4093671/__pixel__', [1, 1], 'div-gpt-ad-pixel').addService(googletag.pubads()) googletag.pubads().enableSingleRequest(); googletag.enableServices(); }) </script><script type="text/javascript" src="https://try.abtasty.com/c08aeadc32b24da5aeee48542ac7879a.js"></script><script> window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'userStatus': 'Gratuit', }); </script><span class="js_modal_button" data-modal="user_data_modal" style="cursor:pointer;"></span><div id="user_data_modal" class="modal modal--large p-0 " ><div class="modal__content "></div><div class="modal__footer"></div></div><div class="esi_h" id="ud" style="width:0;margin:0;height:0;overflow:hidden;"> <div data-ga_event="onLinkClick" data-ga_categorie="stats_teasing_click" data-ga_action="866" ><div style="display:none;" data-ga_event="onload" data-ga_categorie="stats" data-ga_action="teasing" data-ga_libelle="866"></div><div style="display:none;" data-ga_event="onload" data-ga_categorie="sticky-btn-light" data-ga_action="transcript" data-ga_libelle="sticky-btn-light_non-inscrits_transcript_ts-transcript_bg-bleu"></div><div id="t866" style="display:block"><div id="teasing_866" style="position:fixed;bottom:0;left:0px;width:100%;z-index:998;" > <div style="align-items: start;display:flex;font-size: 0.9rem;padding:7px;background:#004eff;color:#ffffff;"> <div style="flex:1;display:flex;justify-content: center;"> <a target="_top" style="flex:1;display:flex;justify-content: center;text-decoration:none;color:inherit;" href="/signup?utmzb_campaign=transcript++sticky-btn-light_non-inscrits_transcript_ts-transcript_bg-bleu+ts-transcript_bg-bleu+&utmzb_content=++++&utmzb_source=sticky-btn-light&utmzb_medium=non-inscrits"> <div style="align-self: center;margin-right: 5px;"> <span style=" "> All transcripts on over 9000 companies, on the day they post their earnings! </span> <span class="c-inline cs-none" > <div style=" color:#ffffff; font-weight:700; "> Unlock them now! </div> </span> </div> <div class="c-none cs-block" > <div style=" box-shadow:1px 1px 2px #5c5c5c; padding:3px 15px; color:#000000; background:#ffffff; margin:0px 0px 0px 15px; "> Unlock them now! </div> </div> </a> </div> <div class="ajax_close_teasing866" style="padding:0px 10px;"> <svg class="bi bi-x-circle-fill " xmlns="http://www.w3.org/2000/svg" style="margin-top:5px;cursor:pointer;margin-left:auto;width:20px;" fill="#ffffff" alt="fermer" viewBox="0 0 16 16"> <path data-idteasing="866" class="ajax_close_teasing866" d="M16 8A8 8 0 1 1 0 8a8 8 0 0 1 16 0zM5.354 4.646a.5.5 0 1 0-.708.708L7.293 8l-2.647 2.646a.5.5 0 0 0 .708.708L8 8.707l2.646 2.647a.5.5 0 0 0 .708-.708L8.707 8l2.647-2.646a.5.5 0 0 0-.708-.708L8 7.293 5.354 4.646z"/> </svg> </div> </div> </div> <script> document.addEventListener("click", function(event) { if (event.target.matches(".ajax_close_teasing866")) { var element = event.target; var xhr = new XMLHttpRequest(); xhr.open("GET", "/mods_a/ajax_teasing.php?action=hide&idT="+element.getAttribute('data-idteasing'), true); xhr.setRequestHeader("Content-Type", "application/json"); xhr.onreadystatechange = function() { if (xhr.readyState === 4 && xhr.status === 200) { element.closest('[id*="teasing_"]').remove(); } }; xhr.send(); } }); document.addEventListener("click", function(event) { if (event.target.matches(".ajax_close_teasing_ws866")) { var element = event.target; element.closest('[id*="teasing_"]').remove(); } }); </script> </div></div></div><script> function onloadUI() { } function onunloadUI() { } </script> <script>var country_location = "IN"; function startAdsServiceD(){ gaEvent('adspv', 'internal_start', 'IN'); $(document).ready(function() { displayViewableAds('internal'); $( window ).scroll(function() { displayViewableAds('internal'); }); }); } $(document).ready(function() {gaEvent('adspv', 'internal', 'IN');}); googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US'); googletag.pubads().setTargeting('UserType', 'free'); googletag.pubads().setTargeting('Content', 'news'); var iAdsPos = 0; aAdsList.forEach(function(e) { if (aAdsListSize[iAdsPos] !== null && (aAdsListCA[iAdsPos] === null || aAdsListCA[iAdsPos] == country_location)) { googletag.defineSlot('/4093671/_'+e+'_/internal_'+e, aAdsListSize[iAdsPos], 'zpp'+e).addService(googletag.pubads());}iAdsPos++;}); googletag.enableServices(); var iAdsPos = 0; aAdsList.forEach(function(e) { if (aAdsListSize[iAdsPos] !== null && (aAdsListCA[iAdsPos] === null || aAdsListCA[iAdsPos] == country_location)) { googletag.display('zpp'+e); }iAdsPos++;}); try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)} }); $(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } }); </script> </div><script async defer src="https://ats-wrapper.privacymanager.io/ats-modules/7b190444-c935-406d-8261-160ca079fd9a/ats.js"></script><script data-action="{} Tags usage" data-version="3" data-type="cached"> gtag('config', 'G-W5MZBYLHSG', { 'anonymize_ip': true, 'page_path': "/news/medartis-delivers-15-3-organic-sales-growth-in-h1-and-lifts-sales-guidance-for-the-full-year-ce7c51dcdc80f221" , 'content_group1': 'Actions' , 'content_group2': 'eqs' , 'content_group3': 'action/communique_de_presse' }); </script><script data-action="live-opts"> const liveHtml_BASE_URL = "https://live.marketscreener.com"; const liveHtml_AUTH = { hkKey: "b20241c564a2d5bf0e9fb4ca1839c10b", pvKey: "b67b1e38aa5e3b9fbd9d9dea4960c8a2", uKey:"L25ld3MvbWVkYXJ0aXMtZGVsaXZlcnMtMTUtMy1vcmdhbmljLXNhbGVzLWdyb3d0aC1pbi1oMS1hbmQtbGlmdHMtc2FsZXMtZ3VpZGFuY2UtZm9yLXRoZS1mdWxsLXllYXItY2U3YzUxZGNkYzgwZjIyMQ==" }; const liveHtml_TOJS = []; </script><div id="editionModal" class="modal modal--large "><span class="js_modal_close modal__close-btn"editionModal')"><i class="bi-x txt-s7 txt-black"></i></span><div class="modal__content"><div class="modal_title-custom pt-15"><div class="grid align-center"><i class="pl-10 bi-globe2 globe-icon c-none cm-inline"></i><div><p class="pl-10 txt-bold m-0">Select your edition</p><p class="txt-s1 txt-muted m-0 pl-10">All financial news and data tailored to specific country editions</p></div></div></div><div class="grid mb-5 mt-15"><div class="c-12 cm-3 c-flex gcol gbetween"><div class="mb-10"><p class="region-title pl-5 mb-10">NORTH AMERICA</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center active" data-edition="en_US" href="/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/us.png" loading="lazy" alt="MarketScreener"></div><span class="country-name">United-States</span></a><a class="country-item align-center " data-edition="en_CA" href="//ca.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ca.png" loading="lazy" alt="MarketScreener Canada"></div><span class="country-name">Canada</span></a></div></div><div class="mb-10"><p class="region-title pl-5 mb-10">MIDDLE EAST</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center " data-edition="en_SA" href="//sa.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/sa.png" loading="lazy" alt="MarketScreener Saudi Arabia"></div><span class="country-name">Saudi Arabia</span></a><a class="country-item align-center " data-edition="en_AE" href="//ae.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ae.png" loading="lazy" alt="MarketScreener UAE Emirates"></div><span class="country-name">United Arab Emirates</span></a></div></div></div><div class="c-12 cm-6 "><div class="mb-10"><p class="region-title pl-5 mb-10">EUROPE</p><div class="c-flex flex-wrap countries-grid--2"><a class="country-item align-center " data-edition="fr_FR" href="//www.zonebourse.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/fr.png" loading="lazy" alt="Zonebourse"></div><span class="country-name">France</span></a><a class="country-item align-center " data-edition="de_DE" href="//de.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/de.png" loading="lazy" alt="MarketScreener Deutschland"></div><span class="country-name">Deutschland</span></a><a class="country-item align-center " data-edition="fr_CH" href="//ch.zonebourse.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ch.png" loading="lazy" alt="Zonebourse Suisse"></div><span class="country-name">Suisse</span></a><a class="country-item align-center " data-edition="de_CH" href="//ch.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ch.png" loading="lazy" alt="MarketScreener Schweiz"></div><span class="country-name">Schweiz</span></a><a class="country-item align-center " data-edition="it_IT" href="//it.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/it.png" loading="lazy" alt="MarketScreener Italia"></div><span class="country-name">Italia</span></a><a class="country-item align-center " data-edition="de_AT" href="//at.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/at.png" loading="lazy" alt="MarketScreener Österreich"></div><span class="country-name">Österreich</span></a><a class="country-item align-center " data-edition="nl_BE" href="//be.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/be.png" loading="lazy" alt="MarketScreener België"></div><span class="country-name">België</span></a><a class="country-item align-center " data-edition="nl_NL" href="//nl.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/nl.png" loading="lazy" alt="MarketScreener Nederland"></div><span class="country-name">Nederland</span></a><a class="country-item align-center " data-edition="es_ES" href="//es.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/es.png" loading="lazy" alt="MarketScreener España"></div><span class="country-name">España</span></a><a class="country-item align-center " data-edition="sv_SE" href="//se.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/se.png" loading="lazy" alt="MarketScreener Sverige"></div><span class="country-name">Sverige</span></a><a class="country-item align-center " data-edition="en_GB" href="//uk.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/gb.png" loading="lazy" alt="MarketScreener UK"></div><span class="country-name">United Kingdom</span></a></div></div></div><div class="c-12 cm-3 "><div class="mb-10"><p class="region-title pl-5 mb-10">APAC</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center " data-edition="en_AU" href="//au.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/au.png" loading="lazy" alt="MarketScreener Australia"></div><span class="country-name">Australia</span></a><a class="country-item align-center " data-edition="en_IN" href="//in.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/in.png" loading="lazy" alt="MarketScreener India"></div><span class="country-name">India</span></a><a class="country-item align-center " data-edition="en_HK" href="//hk.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/hk.png" loading="lazy" alt="MarketScreener Hong Kong"></div><span class="country-name">Hong Kong</span></a></div></div></div></div></div></div><div id="notifications-portal" data-flashes="[]" ></div><div id="g_id_onload" data-client_id="420803176712-vlrh8sjg6d8d2ljv2t5o05foig31q9qd.apps.googleusercontent.com" data-login_uri="https://www.marketscreener.com/login/google/" data-auto_prompt="true" data-itp_support="true" ></div><script src="https://cdn.zonebourse.com/static/assets/mPulse/mpulse-surperformance.js" async></script><input type="hidden" id="csrf-token" value="9acd45.5Vt5PCxFfkh2kQuCDVySmsELleja31wCd5ZVBYaMWQo.jGwUclkkHx4cwV7nZyXa_65t3oKujGtyQuM-PeXEEDyBOApVXgIdBz3fQg"></body></html>

Company analysis